Clinic Roundup

 Juventas Therapeutics Inc., of Cleveland, treated the first patient in its Phase II STOP-HF trial. The 90-patient, placebo-controlled, randomized, double-blind study is evaluating the safety and efficacy of JVS-100 in late-stage heart failure.